FibroBiologics Regains Nasdaq Compliance
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
FibroBiologics fixed a problem and is allowed to keep trading on Nasdaq, which is the big stock exchange. When a company fixes compliance issues, it shows they're working to stay in good standing, though it doesn't tell us if their medicines will work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.